Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 363

1.

B-cell depleting agents for ANCA vasculitides: a new therapeutic approach.

Gómez-Puerta JA, Quintana LF, Stone JH, Ramos-Casals M, Bosch X.

Autoimmun Rev. 2012 Jul;11(9):646-52. doi: 10.1016/j.autrev.2011.11.007. Epub 2011 Nov 21. Review.

PMID:
22146313
2.

Rituximab in the treatment of anti-neutrophil cytoplasm antibody-associated vasculitis.

Jones RB.

Nephron Clin Pract. 2014;128(3-4):243-9. doi: 10.1159/000368580. Epub 2014 Nov 14. Review.

PMID:
25401382
3.

The role of rituximab in the treatment of ANCA-associated vasculitides (AAV).

Daikeler T, Kistler AD, Martin PY, Vogt B, Huynh-Do U.

Swiss Med Wkly. 2015 Feb 6;145:w14103. doi: 10.4414/smw.2015.14103. eCollection 2015. Review.

4.

Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement.

Geetha D, Specks U, Stone JH, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Fessler BJ, Ding L, Tchao NK, Ikle D, Jepson B, Brunetta P, Fervenza FC; Rituximab for ANCA-Associated Vasculitis Immune Tolerance Network Research Group.

J Am Soc Nephrol. 2015 Apr;26(4):976-85. doi: 10.1681/ASN.2014010046. Epub 2014 Nov 7.

5.

[ANCA-associated vasculitis].

Holle JU.

Internist (Berl). 2015 Jan;56(1):41-50; quiz 51-2. doi: 10.1007/s00108-014-3613-8. German.

PMID:
25502657
6.

Impact of rituximab trials on the treatment of ANCA-associated vasculitis.

Alberici F, Jayne DR.

Nephrol Dial Transplant. 2014 Jun;29(6):1151-9. doi: 10.1093/ndt/gft318. Epub 2013 Oct 14. Review.

PMID:
24126571
7.

Rituximab in induction therapy for anti-neutrophil cytoplasmic antibody (ANCA) vasculitis.

Niles J.

Clin Exp Immunol. 2011 May;164 Suppl 1:27-30. doi: 10.1111/j.1365-2249.2011.04363.x. Review.

8.

Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis.

Smith RM, Jones RB, Guerry MJ, Laurino S, Catapano F, Chaudhry A, Smith KG, Jayne DR.

Arthritis Rheum. 2012 Nov;64(11):3760-9. doi: 10.1002/art.34583.

9.

[The role of rituximab in the treatment of ANCA-associated systemic vasculitis].

Roccatello D, Vangelista A, Pani A.

G Ital Nefrol. 2011 Sep-Oct;28(5):474-88. Review. Italian.

PMID:
22028261
10.

[Rituximab for the treatment of ANCA associated vasculitis: the future today?].

Alba MA, Flores-Suárez LF.

Reumatol Clin. 2011 Dec;7 Suppl 3:S41-6. doi: 10.1016/j.reuma.2011.10.006. Epub 2011 Nov 23. Review. Spanish.

11.
12.

Advances in therapy for ANCA-associated vasculitis.

Geetha D, Seo P.

Curr Rheumatol Rep. 2012 Dec;14(6):509-15. doi: 10.1007/s11926-012-0284-0. Review.

PMID:
22895899
13.

Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis.

Rhee EP, Laliberte KA, Niles JL.

Clin J Am Soc Nephrol. 2010 Aug;5(8):1394-400. doi: 10.2215/CJN.08821209. Epub 2010 May 24.

14.

Rituximab in ANCA-associated vasculitis: fad or fact?

Fervenza FC.

Nephron Clin Pract. 2011;118(2):c182-8; discussion c188. doi: 10.1159/000321437. Epub 2010 Dec 16. Review.

PMID:
21160229
15.

S3. Rituximab for ANCA-associated vasculitides: the French experience.

Charles P, Guillevin L.

Presse Med. 2013 Apr;42(4 Pt 2):534-6. doi: 10.1016/j.lpm.2013.01.050. Epub 2013 Feb 26. Review. No abstract available.

PMID:
23453207
16.

Refractory disease in antineutrophil cytoplasmic antibodies associated vasculitis.

Rutgers A, Kallenberg CG.

Curr Opin Rheumatol. 2012 May;24(3):245-51. doi: 10.1097/BOR.0b013e3283529756. Review.

PMID:
22410545
17.

S2. Rituximab for ANCA-associated vasculitis: the UK experience.

Jayne D.

Presse Med. 2013 Apr;42(4 Pt 2):532-4. doi: 10.1016/j.lpm.2013.01.049. Epub 2013 Mar 9. Review. No abstract available.

PMID:
23490639
18.

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial.

Jones RB, Furuta S, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, Savage CO, Segelmark M, Tesar V, van Paassen P, Walsh M, Westman K, Jayne DR; European Vasculitis Society (EUVAS).

Ann Rheum Dis. 2015 Jun;74(6):1178-82. doi: 10.1136/annrheumdis-2014-206404. Epub 2015 Mar 4.

PMID:
25739829
19.

Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type.

Unizony S, Villarreal M, Miloslavsky EM, Lu N, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CM, St Clair EW, Ikle D, Tchao NK, Ding L, Brunetta P, Choi HK, Monach PA, Fervenza F, Stone JH, Specks U; RAVE-ITN Research Group.

Ann Rheum Dis. 2016 Jun;75(6):1166-9. doi: 10.1136/annrheumdis-2015-208073. Epub 2015 Nov 30.

20.

Biologics for ANCA-associated vasculitis.

Murgia G, Firinu D, Manconi PE, Del Giacco SR.

Inflamm Allergy Drug Targets. 2014;13(4):275-87.

PMID:
24998311

Supplemental Content

Support Center